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10
SPR imaging (SPRi) is at the forefront of optical label-free and real-time detection. It offers the 11
possibility of monitoring hundreds of biological interactions simultaneously and from the 12
binding profiles, allows the estimation of the kinetic parameters of the interactions between the13
immobilised probes and the ligands in solution. We review the current state of development of 14
SPRi technology and its application. Commercially available SPRi instruments are covered.15
Attention is also given to surface chemistries for biochip functionalisation and suitable 16
approaches to improve sensitivity. 17
18
Keywords: surface plasmon resonance imaging, SPRi, affinity sensing, immobilisation 19
chemistry, signal amplification immunosensor, aptasensor, optical sensor20
21
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Introduction1
Following its commercial launch in 1990, Surface Plasmon Resonance (SPR) sensing has 2
emerged as a key research tool for pharmaceutical development, food quality control, 3
environmental monitoring and clinical analyses (Homola, 2008). An increasing number of 4
reviews (Fan, 2008; Homola, 2008; Visser, 2008; Jason-Moller, 2006; Pattnaik, 2005), and 5
books (Schasfoort and Tudos, 2008; Homola, 2006) dealing with the fundamentals and 6
applications of SPR-based sensing have been published over the last decade. One of the most7
important advances in the field is the SPR imaging (SPRi), also called “SPR microscopy”, 8
which couples the sensitivity of scanning angle SPR measurements with the spatial capabilities 9
of imaging. SPRi represents a promising and highly versatile affinity sensing platform suitable 10
for an array format. SPRi has been reported for a variety of affinity systems, including 11
DNA/DNA (Hayashi 2008; Piliarik, 2008; Lecaruyer 2006; Nelson, 2001), 12
RNA/DNA (Li 2006; Nelson, 2002), DNA-binding protein (Jeong 2008; 13
Bouffartigues 2007; Wegner 2003), RNA aptamers/protein (Garcia 2008; Li 14
2007; Li 2006), antibody-antigen (Ladd 2008; Liu 2008; Rebe Raz 15
2008; Wong 2008; Yuk 2006) and carbohydrate/protein (Grant ., 2008; 16
Mercey , 2008; Wakao ., 2008; Smith ., 2003). SPRi technology enables affinity 17
interactions to be monitored in real-time and without the use of any label, as in classical SPR 18
sensing, but by using a CCD camera for signal detection both sensorgrams ( resonance signal 19
. time) and images of the chip can be recorded allowing simultaneous analysis of many 20
interactions (up to hundreds).21
22
This review describes SPRi technology and its applications. Commercially available SPRi 23
instrumentation is included with a focus on some key technical features such as the fluidic 24
Page 10 of 35
Ac
ce
pte
d M
an
us
cri
pt
3
system, temperature control, cell and biochip design. Attention is also given to surface chemistry 1
for biochip functionalisation and suitable approaches to improve sensitivity. 2
3
Traditional SPR cf. imaging SPR: features and breakthroughs 4
SPR transduction belongs to the class of refractometric sensing devices, which use evanescent 5
waves to investigate surface phenomena. Changes in refractive index at the sensing surfaces due 6
to analyte binding influence the resonant angle and this shift is used to generate a real-time 7
signal. Thus labelling is not required. Commercial SPR instruments are available from numerous 8
suppliers (Homola, 2008), the most frequently reported being the Biacore™ system (GE 9
Healthcare). SPR platforms can be classified according to three modulation approaches: angular, 10
wavelength and intensity (Homola, 2006).11
12
In contrast to scanning angle SPR and scanning wavelength SPR (traditionally termed “SPR 13
spectroscopy”), SPRi systems are generally based on intensity modulation, measuring the 14
reflectivity of monochromatic incident p-polarised light at a fixed angle. The polariser permits 15
measurements both with p-polarised and s-polarised light, but the latter is used only as reference 16
signal to improve the image contrast and to eliminate artefacts. In the majority of cases, SPRi 17
instruments use a high refractive index prism in the Kretschmann configuration (Kretschmann 18
and Reather, 1968). An alternative is the use of grating couplers (Wassaf , 2006). The19
sensing surface of the prism is coated with a thin metal layer (usually gold or silver, 20
approximately 50 nm in thickness), on which surface plasmons (SPs) are excited by matching 21
SPs and evanescent wave (EW) propagation constants. The resonance conditions depend on the 22
characteristics of the prism, metal and dielectric medium. The best resonance conditions are23
usually achieved by varying the incident angle of the light on prism. A charge coupled device24
(CCD) camera collects the reflected light, allowing the visualisation of the whole biochip in real 25
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time. If the sensor surface is divided into multiple sensing spots, , microstructured, the device 1
can be used as a multichannel sensor. 2
3
SPRi offers two main advances over conventional SPR: the ability to visualise the entire biochip 4
surface in real time and the chance to monitor up to hundreds of molecular interactions 5
continuously and simultaneously in a multi-array format of molecular probes formed as circular 6
or square spots. It is also possible to control the quality of the spotted array by viewing the 7
surface image to accurately select the measurement area. These Regions of Interest (ROIs) are 8
selected, for example, according to shape, size, and quality of the spot to enhance experimental 9
results. Direct image control of the surface also helps identify and reduce the ubiquitous problem 10
of non-specific binding by defining spots without receptors and spots on gold, to be used as 11
negative control surfaces (negative control ROIs). The ability to immobilise many receptors (up 12
to hundreds) on the surface and to monitor the kinetic parameters of biospecific interactions 13
simultaneously in a real-time and label-free microarray format is a tantalising opportunity. Spots 14
(currently from 50  Pm2 up to 1 cm2) can be created both manually or by automatic spotters.15
16
Characteristics of SPR imaging instruments on the market 17
Many in-house SPRi instruments have been described  (Ladd ., 2008; Ruemmele ., 18
2008; Chinowsky , 2007; Lecaruyer , 2006), but a number of commercial SPRi 19
instruments have recently been launched on market by, for example, GWC Technologies 20
(Madison, USA), IBIS Technologies B.V. (Hengelo, The Netherlands), Genoptics Bio 21
Interactions (Orsay, France) and GE Healthcare (Uppsala, Sweden).22
23
Except for the BiacoreTM Flexchip (GE Healthcare), configured as a grating coupler sensor, the 24
Kretschmann configuration is adopted (Fig. 1a). The measurement is carried out by fixing a 25
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single working angle that corresponds to the greatest plasmon curves slope of interest and 1
recording the analytical datum as the intensity variation of the reflected light at that angle for 2
each ROI is detected (Fig. 1b). At the same time interactions are displayed as sensorgrams (Fig. 3
1c). Only the IBIS iSPR instrument operates in scanning angle mode; it directly records the so-4
called “SPR dip” angle shifts linked to analyte binding. The main difference between these two 5
optical assets relies on the dynamic range of the recorded variable (angle shift or reflectivity 6
change) refractive index change (and, consequently, mass density change). In particular, 7
measurements conducted in fixed angle mode limit the linear relationship range between 8
reflectivity and change in mass to the linear portion of the plasmon curve. This range 9
corresponds to approximately 5% variation of reflectivity and about 50 mdeg of the SPR dip 10
(Nelson 2001).11
12
Performance comparisons have been reported (Beusink 2008; Rebe Raz ., 2008; 13
Lokate 2007). Beusink, (2008), using the IBIS iSPR, developed a 24-spot biosensor 14
by immobilising both a short peptide (2.4 kDa) and IgG (150 kDa), modified with biotin, to test 15
the dynamic range, limit of detection and standard deviation of the measurement of anti-biotin 16
mouse IgG. The experiment was conducted in parallel with the SPRimager®II system (GWC 17
Technologies) and fluorescence microscopy. The results showed that IBIS iSPR angle scanning 18
mode yielded a 10-fold larger dynamic range compared to the SPRimager®II system, allowing 19
the detection of molecules of very different molecular weight simultaneously immobilised on the 20
same sensor chip. 21
22
23
24
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The performance of a biosensor is strictly correlated with the control of the hydrodynamic 1
conditions on the sensor surface and, consequently, the liquid handling system plays a crucial 2
role. Flow-through and cuvette systems are available. The first system presents the benefit of 3
well-defined hydrodynamic conditions during measurements without rebinding effects. 4
Microfluidic networks have attracted recent attention and studies to minimise diffusion problems 5
and on analyte mass transport effects have appeared (Kanda ., 2004; D’Agata ., 2008).6
Cuvette systems, allows multiple sample additions. Moreover the cuvette approach reduces 7
sample volume require thus it is very suitable when low volumes are available and/or in case of 8
analyte with low binding constants. Most of SPRi instruments offer both flow through and 9
cuvette systems. 10
11
Another key feature in all SPRi platforms is the flow cell. Early work by Berger (1998) 12
reported one- and two-dimensional multichannel immunosensing using a homemade SPRi 13
platform equipped with a four-channel flow cell governed by a four-channel peristaltic pump. 14
Initially, the cell was placed in contact with the biochip and antibody was coated onto its surface 15
by flowing through the channels. The four-channel cell was then turned 90°, thus creating 16 16
independent sensing areas of ~1 mm2, and an equal number of antibody/antigen signals on a 17
single biochip surface. This multichannel approach has been recently applied to commercial 18
available instrumentation (ProteOn™ XPR36, Bio-Rad Laboratories, CA, USA) based on 19
traditional SPR transduction. At present, the flow cell is designed to let the same analyte solution 20
interact with an array of different probes, minimising the high variability exhibited by21
multichannel systems. The internal volumes of most flow cell range from few up to hundreds of 22
nanoliters and only slight differences in shape can be found between the different instruments.23
The SPRimager®II system (GWC Technologies) can be equipped with flow cells of 24 and 12 24
µL internal volume and measurements can be achieved both in stop-flow and recirculation mode. 25
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IBIS Technologies supplies the iSPR instrument with standard flow cells (30 µL) and cuvettes 1
(100 µL) and the minimum sample volume is 50 µL. SPRi-Plex and SPRi-Lab+ (Genoptics Bio 2
Interactions) not allow sample recirculation and the internal volume of the equipped cells is 3
about 6 µL. The minimum volume/injection ranges from about 20 µL for SPRi-Lab+ up to 2004
µL for SPRi-Plex model. The Biacore family of instrumentation has also recently launched the 5
Flexchip (GE Healthcare) for up to 400 hundred simultaneous measurements. The minimum 6
required volume is       P /    D O W K R X J K   W K H   F H O O   Y R O X P H   L V   R I       /    7 K L V   L V   D Q   L P S R U W D Q W   O L P L W D W L R Q 7
for application of the system to molecular biology research, but competitive for proteomic 8
studies.9
Some commercially available instruments have temperature control. The IBIS-iSPR has high 10
precision temperature control and both the sample deck (with microtitre plate) and sensor can be 11
cooled or heated with 0.01-degree precision (°C) facilitating thermodynamic kinetic analyses. 12
SPRi-Plex, from Genoptics’ has a Peltier temperature control system between 15°C and 40°C 13
with a 0.1°C precision and a 0.01°C stability. Thermostatic control can be also obtained with the 14
fully automated Flexchip  in the range 25°-37° C.15
To address the lack of temperature control some groups have reported in house developed 16
temperature control from 25 to 70°C (Corne 2008) or temperature scanning to perform 17
melting curves on DNA duplexes for point mutation detection (Fiche , 2008). 18
19
SPRi Biochips20
Immobilisation of the molecular probe should be reproducible, retain biological activity and 21
orientate the receptor for optimal binding. Moreover the number and type of probes can vary, 22
depending of the application under study. It is not easy to fulfil all these requirements thus ready 23
to use chips are available from different companies commercialising SPRi instrumentation for 24
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not experienced users. Alternatively many groups familiar with biosensors, report about 1
interesting chemical approaches for the SPRi biochips development.2
The common strategy for realising spots is to isolate small areas of the surface and to surround3
them by an antifouling environment, thus reducing non-specific SPRi signals from background.4
An example is the commercial SpotReady™ gold chip (GWC Technologies). 5
Pre-coated chips are also available with different types of chemicals (e.g.  Z-terminated amine6
carboxylic functionalities from IBIS Technologies) suitable for further chemical modifications. 7
Electropolymerisation of pyrrolated-conjugates prepared using pyrrole-NHS, pyrrole-8
phosphoramidite and pyrrole-hydrazide is also applied for biochip development by Genoptics9
Behind ready to use biochips, one can develop suitable chemistry for bioreceptor immobilisation. 10
11
Immobilisation methods12
In SPRi the sensor surface is almost always a thin layer of gold. Most immobilisation techniques 13
involve a first layer of a chemical linker directly bound to the gold, allowing subsequent 14
anchoring of molecules of interest. The main objective is to create a support structure for the 15
receptor that ensures stability under working conditions and access to the analyte, while16
minimising receptor detachment. The use of a blocking agent prevents non-specific adsorption. 17
A variety of chemical strategi s have been reported for SPRi-based sensing.18
A favoured immobilisation method is the use of a self-assembled monolayer (SAM) on the gold 19
surface, which increases the degrees of freedom of the probe and, consequently, those of binding20
target molecules. SAMs can be formed by thiol-modified biomolecules, DNA (Manera 21
, 2008) and RNA (Piliarik 2008) sequences, directly attached to the gold surface by22
exploiting its high affinity with thiol groups (Fig. 2). Alternatively, the receptor can be 23
covalently attached via alkanethiols and alkoxylanes containing  Z-terminated amine (Lee ., 24
2005; Smith , 2003), hydroxylic (Mannelli ., 2007) or carboxylic (Liu , 2008; Park 25
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., 2008; Mannelli , 2007) functional groups (Fig. 2). Probe immobilisation to 1
polyelectrolyte films via electrostatic interactions has also been reported. In particular, 11-2
mercaptoundecanoic acid (MUA) modified gold surfaces were exposed to a polyelectrolyte film 3
of branched poly(ethylenimine) (PEI) (Mannelli 2007), in which the amino groups bind the 4
carboxylic end of the MUA electrostatically. The high-density extravidin layer then strongly 5
binds the biotinylated probes (Bassil 2003) via the extravidin–biotin complex (Fig. 2).6
7
Alternatively, SAMs were formed by mixtures of 7 parts to 3 1-mercapto-11-8
undecyltetra(ethylene glycol) (OEG) and carboxylic acid-capped hexa(ethylene 9
glycol)undecanethiol (COOH-OEG). Carboxylic groups of COOH-OEG were then activated 10
with N-hydroxysuccinimide (NHS) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 11
hydrochlorid (EDAC) for antibody immobilisation by amino-coupling (Ladd 2008) (Fig. 12
2). Finally, a SAM layer comprising DNA sequences and OEG was created on a gold surface for13
the simultaneous detection of DNA and protein analytes (Ladd 2008a). Thiol-modified single-14
stranded DNA sequences were spotted onto gold-coated glass substrates, which were then 15
immersed in an OEG-terminated thiol solution. This last step created a protein-resistant surface 16
background and improved the orientation of the DNA molecules. Antibodies conjugated to 17
complementary single-stranded DNA sequences were immobilised on the surface through DNA 18
hybridisation. By converting only part of the DNA array into a protein array, both nucleic acid 19
and proteins could be immobilised.20
21
Corn and co-workers have developed immobilisation protocols over the last decade for 22
immobilising nucleic acids (DNA and RNA probes, RNA aptamers), peptides, proteins and 23
carbohydrates. Their fabrication procedures uses a reversible protecting groups to manipulate 24
surface properties during array construction (Wegner 2004; Brockman 2000) to 25
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spatially confine aqueous solutions. A monolayer of 11-mercaptoundecylamine (MUAM) is1
adsorbed via self-assembly onto an evaporated gold thin film, which can then be reversibly 2
protected using organic protecting molecules. In one of the most used methods, a reversible 3
amine, 9-fluorenylmethoxycarbonyl (Fmoc), acts as protecting group to form a hydrophobic 4
surface. By ultraviolet (UV) photo-patterning squares of bare gold are then obtained and further 5
exposed to MUAM. Thiol-modified DNA is covalently attached to the MUAM squares using a 6
bifunctional linker, the sulfosuccinimidyl 4-( -maleimidomethyl)cyclohexane-1-carboxylate 7
(SSMCC). The linker contains a N-hydroxysulfosuccinimide ester (NHSS) functionality 8
(reactive toward amines) and a maleimide functionality (reactive toward thiols) (Smith 9
2003). Alternatively single-stranded, thiol-modified DNA is immobilised using SATP ( -10
Succinimidyl S-acetyl-thiopropionate). Deprotection of SH group on the surface is achieved 11
using Dithiothreitol (DTT), a small redox molecule, leaving the sulfhydryl to react with 12
dipyridyl disulphide (DPDS) to create a pyridyl disulfide surface. Finally a thiolated molecular 13
probe can be bound to the surface by an exchange reaction between the pyridyl sulphide and the 14
thiol group of the probe (Fig. 2). 15
16
The formation of a hydrogel film composed of carboxymethyl dextran covalently linked to the 17
gold surface with the SAM layer is a widely used method to immobilise the probe for SPR and 18
piezoelectric sensing (Tombelli 2005; Löfås 1995; Löfås and Johnsonn, 1990). By 19
activating the caboxymethyl groups, amino-coupling of protein receptors can be achieved. This 20
approach has been adopted in SPRi for peptide and antibody immobilisation (Beusink 21
2008). Alternatively, biotinylated molecular probes can be attached via avidin/streptavidin 22
binding previously immobilised using the aforementioned dextran chemistry (Mannelli 23
2007) (Fig. 2). 24
25
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One limitation of amino-coupling is the lack of control of receptor orientation, since coupling 1
can occur randomly with any aminic group on the side-chains. In the case of antibody arrays this 2
implies a reduction in the biosensor sensitivity and reproducibility. A number of papers deal with 3
new immobilisation procedures to overcome these drawbacks. For antibody arrays, genetically 4
engineered bacteria were employed to produce protein G with cysteine residues at 5
the N-terminus allowing orientation (Lee 2007) (Fig. 3). Cysteine residues can be 6
genetically introduced into the specific site of the target protein, and this modified protein forms 7
a properly oriented protein layer through the thiol group adsorption on the gold surface in either 8
thiolate or disulfide form (Kallwass 1993) for biosensor development (Di Felice and 9
Selloni, 2004; Persson 1990). Protein G was used as an affinity receptor for antibody 10
immobilisation affording better orientation of immobilised antibodies as well as a higher SPRi 11
sensitivity against antigen targets. Recently, a modified antibody immobilisation introducing a 12
novel linker, protein G-DNA conjugate, was reported (Jung 2007) that possesses the 13
strengths of both protein G and DNA-directed immobilisation. DNA-directed immobilisation14
allows spatial assembly of target proteins on DNA-functionalised assay surfaces (Schroeder 15
2009), resulting in robust and stable chemical linkers (Fig. 3) for SPR transduction and 16
offering possibilities for SPRi. 17
18
Another immobilisation method involves polymeric species, mainly based on polypyrrole 19
(Cosnier 2003). Livache and colleagues developed an electropolymerisation technique for 20
SPRi using the electrochemically directed copolymerization of pyrrole and oligonucleotides 21
bearing on their 5' end a pyrrole moiety (Bidan 2000) (Fig. 3). The resulting polymer film 22
on the electrode consists of pyrrole chains bearing covalently linked oligonucleotides (a mixed 23
solution of DNA-pyrrole and pyrrole monomers). Initially developed for the construction of 24
DNA chips, the polypyrrole approach has been then extended to other biochemical compounds, 25
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mainly proteins (Grosjean 2005) and oligosaccharides (Mercey 2008). The 1
electropolymerisation reaction is based on an electrochemical process allowing a very fast 2
coupling of the probe directly to a gold working electrode, without the need for further chemical 3
linkers.4
5
Very recently, in order to synthesise oligonucleotide probes , a quite different approach 6
has been proposed by Lockett (2008), to create a more resistant surface to oxidation and 7
photodegradation. A lamellar structure in which a thin layer of amorphous carbon was deposited 8
onto the gold thin film was developed. Carbon-based surfaces can be readily modified with 9
biomolecules by attachment of alkene-containing molecules by UV light-mediated formation 10
of carbon-carbon bonds. The surface was further functionalised with 9-decene-1-ol leading to 11
hydroxylic terminated surface, which was modified via photolithographic chemical methods, 12
using oligonucleotide bases modified with a photolabile 3’-nitrophenylpropyloxycarbonyl-13
(NPPOC-) protecting group (Fig. 3). 14
15
The best choice of surface attachment chemistry is not yet clearly established mainly because it 16
depends on many factors such as the biomolecule type to be immobilised, the sample medium 17
and the detection method.18
19
4. Strategies for signal amplification20
Typical DNA samples contain attomolar or femtomolar concentrations, which are well below the 21
nanomolar detection limit SPRi. Hence, sample enrichment (PCR amplification), has been 22
generally applied (Goodrich , 2004a) although in few cases DNA sequences have been 23
detected directl extracted from plant using piezoelectric sensing (Minunni , 2005), 24
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from human lymphocytes by traditional SPR (Minunni , 2007) and from bacteria by SPRi 1
(Nelson 2002).2
3
In order to increase the sensitivity of SPRi, signal amplification has been developed by: a) 4
increasing the SPR output signal through mass or enzymatic processes at the receptor/analyte 5
adduct; b) increasing of the intensity of the evanescent field by structuring the chip surface. Mass 6
enhancement is achieved by addition of molecules which selectively interact with the receptor-7
ligand complex formed at the surface. It was first applied to SPRi for DNA detection  by Jordan 8
(1997), who combined the hybridisation step with subsequent biotin/streptavidin binding 9
(Fig. 4). Both mass and enzyme-based enhancements have been applied to the detection of the 10
signalling protein Vascular Endothelial Growth Factor (VEGF) at 1 pM physiological 11
concentration (Li . 2007). A VEGF-specific aptamer bound the protein, followed by the 12
addition of biotinylated anti-VEGF antibody (sandwich-type assay). The SPRisignal was further 13
amplified using an anti-biotin conjugated horseradish peroxidase (HRP) which, in presence of an 14
HRP substrate such as 3,3’,5,5’-tetramethylbenzidine (TMB), created a localised dark-blue 15
precipitation reaction with SPRi signal enhancement (Fig. 4).16
17
DNA-linked gold nanoparticles have also been used for SPRi signal amplification with 18
immobilised peptide nucleic acid (PNA) sequences to detect point mutations. The target 19
sequences hybridise the PNA probe on the chip surface and amplification is achieved by DNA-20
modified nanoparticles binding to a different region of the target sequence (Fig. 5). Selective and 21
ultrasensitive (1 fM) mismatch recognition was successfully achieved (D’Agata 2008). 22
Fang . (2006) reported a similar approach using a polyadenine (polyA) tail, synthesised 23
, added to the target sequence to bind its complementary LNA (Locked Nucleic Acid) probe. 24
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PolyT-modified nanoparticles, binding the polyA tails were then added to form a ternary surface 1
complex. The reported detection limit for 19-23 mers miRNA was of 10 fM (Fig. 5). 2
3
A combination of surface hybridisation, surface ligation and nanoparticle amplification has been 4
applied to point mutation detection (Li 2006a) by exploiting signal magnification obtained 5
only when DNA sequences were fully matched, not containing Single Nucleotide 6
Polymorphisms (SNPs). Arrays of two sets of probes, differing only in the last nucleotide at their 7
3’ ends specific to the SNP (Fig. 6, grey bars showed in step 1) were exposed to a target solution8
(blue bars) containing a second DNA sequence (“ligation probe DNA”, orange bar) and Taq 9
DNA ligase enzyme. Duplexes were formed (Fig. 6; Step 1) where Taq DNA ligase could only 10
extend the probe sequences with the ligation probe if the receptor did not contain the SNP. After 11
ligation, treatment with 8 M urea selectively denaturated the adducts containing the SNP. 12
Finally, nanoparticles modified with oligonucleotides complementary to the ligation probe DNA13
were added. The SPRi signal, recorded only where the ligation occurred, revealed if the target 14
DNA contained the SNP (Fig. 6, step 2). The detection limit was 1 pM using 36 mer 15
oligonucleotides and the system was applied to point mutation detection in the BRCA1 gene, 16
which is a breast cancer diagnostic. 17
18
A novel approach for DNA detection used RNase H in conjunction with RNA microarrays 19
(Goodrich 2004 & 2004a) (Fig. 7). The exonuclease selectively destroys RNA sequences 20
only in RNA-DNA heteroduplexes, releasing the DNA back to into solution. A single-stranded 21
RNA (ssRNA) microarray was exposed to a solution containing both complementary DNA and 22
RNase H (Fig. 7; Step 1). The DNA binds its RNA complement on the surface (Fig. 7, step 2). 23
RNase H then binds to this heteroduplex, selectively hydrolysing the RNA probe (Fig. 7, step 3), 24
and then releasing the DNA complement back into solution (Fig. 7, step 4). The released DNA 25
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molecule is then free to bind to another RNA probe on the surface, so that a single DNA 1
molecule can initiate the destruction of many surface-bound RNA probes (Fig. 7, step 5). With2
sufficient time, all of the RNA probe molecules are removed from the surface resulting in a3
decrease of the SPRi signal (Fig. 7, step 6). Hence, one sequence could in theory prime the 4
enzymatic catalysis and lead to the destruction of the heteroduplexes on the surface to generate 5
an observable SPRi signal. In practice, the detection limit was 1000 times improved allowing 6
DNA detection down to 1fM.7
8
Other forms of SPRi amplification focus on surface engineering. Long-Range Surface Plasmons 9
(LRSPs) are surface electromagnetic waves that can be created on thin metallic films imbedded 10
between two identical dielectric media. LRSPs have been known for almost thirty years (Quail 11
1983), but have only recently been used for the characterisation of thin-films or for 12
bioaffinity measurements. Wark (2005) used SPRi to demonstrate the suitability of LRSPs 13
for molecular detection and for thin-film sensing in general. A micrometric layer of a 14
commercially available inert, optically transparent material (Cytop, CTL-809M.) with a 15
refractive index very close to water was deposited on a prism coupler surface. A gold layer was 16
then vapour-deposited onto the prism surface and chemically modified for probe immobilisation. 17
Results obtained showed that it is possible to enhance the SPRi output signal by about 20% due 18
to the narrow LRSP resonance curve. 19
20
Improvement in sensitivity can also be obtained by ‘‘nanostructuring’’ the SPR interface. Lisboa 21
(2008) patterned the gold surface of SPRi chips using two organothiols, thiolated 22
polyethylene oxide (PEO), which is unsusceptible to protein and cell adhesion, and 23
mercaptohexadecanoic acid (MHD) with a carboxylic group suitable for coupling to the amino 24
group of a bioreceptor. The surface was modified with active ‘‘nanospots’’ for subsequent probe 25
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immobilisation, surrounded by an inert PEO surface. The nanoarrayed surface produced five 1
times the sensitivity for the Human IgG/anti Human IgG immunoreaction compared to the 2
standard uniform immobilisation.3
4
5. SPR imaging transduction in affinity sensing5
Shortly after its introduction by Yeatman and Ash (1987) SPRi was used in a biomolecular 6
application for the imaging of phospholipid monolayer films (Hickel 1989). Since then, 7
SPRi has also been used for surface morphological investigations of many systems, including 8
self-assembled monolayer films (Evans and Flynn, 1995), mono- and multilayer films prepared 9
by Langmuir-Blodgett techniques (Duschl 1996) and multilayer films by alternating10
polyelectrolyte deposition (Nelson 1999). More recently, SPRi was applied in array-type 11
configurations for studying molecular recognitions between nucleic acids, nucleic acids and 12
protein, immunoreactions and interaction with carbohydrates.13
14
5.1 Nucleic acid arrays for SPRi15
Over the past two decades, Corn’s research group has optimised immobilisation chemistries for 16
microarray development for SPRi, mainly focusing on DNA and RNA sequences. SPRi has been 17
applied to hybridisation-based sensing for many applications, including bacterial genotyping, 18
SNP identification and studing DNA repair. Nucleic acid arrays are also providing innovative 19
tools for the survey of biomolecular interactions between DNA and RNA sequences and binding 20
proteins (Jeong 2008; Bouffartigues ., 2007; Wegner ., 2003).21
Opening up the field of genotyping for environmental and clinical applications, detection of 16S 22
ribosomal RNA from with short, unlabelled DNA and RNA sequences by SPRi was 23
successfully demonstrated (Nelson 2002; Nelson 2001). Other research groups 24
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(Manera 2008a; Piliarik 2008, Hottin 2007) have obtained promising results 1
for bacterial pathogens, but data are still scarce for real matrices.2
3
Specific RNA arrays for SPRi have been designed to demonstrate the specificity and affinity 4
between synthetic aminoglycoside antibiotics (kanamycins) and RNA sequences (Nishimura 5
., 2005) to elucidate aminoglycoside-RNA recognition in order to overcome resistance and side 6
effects of antibiotics. It was shown that kanamycins have non-specific, multiple interactions with 7
RNA hairpins and that the binding strenght is not always proportional to the antimicrobial 8
activity.9
10
Due to its capability to discriminate between highly similar nucleotide sequences, SPRi has 11
recently gained the attention of researchers investigating SNPs (Fiche 2008; Hayashi , 12
2008) and gene mutation (Lecaruyer 2006). SPRi applicability for point mutations rapid 13
screening, was demonstrated by Livache’s, using in-house apparatus, performing temperature 14
scans. DNA probe sequences carrying different point mutations were immobilised and15
distinguished perfectly matched duplexes from mismatched ones by virtue of their different 16
melting temperature over ten temperature scans (Fiche 2008). The results showed that 17
imaging coupled with temperature scans can be an efficient and low-cost tool for point mutation 18
detection on DNA chips.19
20
Some crucial enzyme activities have also been investigated using immobilised DNA sequences 21
such as the binding and catalytic properties of DNA N-glycosylase towards damaged DNA sites 22
(Corne 2008; 2008a). DNA N-glycosylases are enzymes involved in Base Excision Repair 23
(BER), which is the major mechanism for correction of damaged nucleobases. A decrease of 24
BER activity is correlated to carcinogenesis and aging and the study of biological interactions 25
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between damaged DNA and repair enzymes have a crucial role in the search for new DNA repair 1
inhibitors and the understanding of DNA repair mechanisms (Baute 2008).2
3
The importance of microRNAs (miRNAs) in gene expression and regulation, as well as in cell 4
function is well established (Williams 2008) and the synthesis of miRNA has been 5
investigated by SPRi (Wark 2008; Fang ., 2006) for possible clinical diagnostic6
applications. Promising high-quality miRNA profiling for simple, rapid and multiplexed 7
analyses is emerging. Another class of nucleic acid sequences, aptamers, represents a 8
competitive tool for proteomic research such as protein biomarker discovery (Tombelli 9
2007). Aptamers are a promising alternative to antibody microarrays for clinical analysis and 10
SPRi aptasensing has already been reported for the detection of human Immunoglobulin E 11
(Wang 2007), human factor IXa (Li 2006) and vascular endothelial growth factor 12
(Li 2007).13
14
5.2 Protein and short peptide arrays for SPRi15
Increasing interest in the analysis of peptides and proteins using array formats with surface-16
sensitive optical techniques like SPRi is prompted by the chance to detect the biomolecular 17
interactions without labelling, which may adversely affect molecular structures. Jung 18
(2005) recently developed protein microarrays for high-throughput SPRi measurements and 19
tested a SPRi platform for protein–protein interactions (Ro 2005; 2006). The approach20
facilitated the study of protein-protein interactions where multiple proteins are involved and 21
demonstrated high-throughput monitoring of affinity-tagged proteins in expression and 22
purification processes (Ro 2005). Moreover, they chose the Human Papilloma Virus E6 23
protein with its binding proteins, the ligase E6AP and the tumor suppressor p53, as a model 24
study to investigate the triple protein interaction (E6/E6AP/p53) that takes place during the viral 25
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infection (Ro 2006). The complex formation induces a degradation of p53 and, 1
consequently causes the transformation of normal cells into malignant cells and work in this area 2
supports the development of new anticancer drugs against HPV-related cervical cancer. More 3
recently, they also reported the study of caspase-3 activation by SPRi (Park 2008). 4
Caspase-3 is an intracellular cysteine protease and plays a crucial role in the apoptotic cell 5
process. Its activation is commonly used as a biomarker for assessment and understanding of 6
apoptosis, and is conventionally detected using an arti  ¿ F L D O   À X R U R J H Q L F   V X E V W U D W H   D Q G   : H V W H U Q 7
blotting. The new method measured a fluorescence signal adapted to SPRi. A chimeric caspase-3 8
substrate (GST:DEVD:EGFP) composed of glutathione S transferase (GST) and enhanced green 9
 À X R U H V F H Q W   S U R W H L Q    ( * ) 3    Z L W K   D   V S H F L D O L V H G   O L Q N H U   S H S W L G H   K D U E R X U L Q J   W K H   F D V S D V H-3 cleavage 10
sequence (DEVD) was developed. Utilizing this caspase-3-dependent proteolytic reporter, they 11
successfully monitored the proteolytic activity of caspase-3. These results confirm that SPRi 12
offers new ways to study protein mechanisms without labelling.13
14
Short peptides play an important role in identifying important residues in protein-protein 15
recognition processes and in the understanding of peptide-DNA interactions and enzymatic 16
modification of peptides. Katayama’s group has recently developed SPRi to explore peptide 17
probes as kinase substrates (Mori ., 2008; Inamori 2005). The synthesis of drugs 18
modulating the activities of particular protein kinases has become a prime focus of the 19
pharmaceutical and biotechnology industry, thus development of high-throughput screening 20
formats for these enzymes is of crucial interest. Mori and colleagues proposed a novel detection 21
system for on-chip phosphorylation of peptide probes and a zinc(II) chelate compound, working22
independently of the amino acid residues on the array, using a single-probe complex, differing 23
from in solution conventional methods (Sola-Penna 2002; Ross 2002). 24
25
Page 27 of 35
Ac
ce
pte
d M
an
us
cri
pt
20
SPRi immunosensor based on antibodies arrays, have been also reported. Work dealt with 1
antibodies orientation for enhancing sensor performance (Jung , 2007; 2008; Lee et al., 2
2007) and assays for candidate cancer biomarkers. Anti-activated cell adhesion molecule/CD 3
166 (anti ALCAM) and anti transgelin-2 (anti TAGLN2) antibodies were employed for the 4
identification and quantitation of the relative ALCAM and TAGLN2 antigens (Ladd 2008) 5
immobilised in array format. The detection limits in buffer were in the ppb range for both 6
targets, which is compatible with physiological levels in human serum (typically 10 to 100 ppb), 7
although high non-specific signals were found in spiked 10-fold diluted commercial serum 8
samples. Better results can be expected by improving the surface chemistry to reduce matrix 9
effects. 10
11
5.3 Carbohydrate microarrays for SPRi12
As mentioned above, carbohydrates are interesting candidates for array format analysis, but 13
publications are sparse due to the lack of reliable methods of fabrication. Smith . (2003) 14
reported the fabrication of mannose and galactose carbohydrate arrays on gold films using poly-15
(dimethylsiloxane) (PDMS) microchannels and their use in SPRi to monitor the binding of the 16
lectins jacalin and concanavalin A (ConA). They quantified the strength of lectin-carbohydrate 17
interactions by determining the adsorption coefficients and the solution dissociation constants for 18
the lectins ConA and jacalin, highlighting the potential of SPRi for weak protein-carbohydrate 19
interaction studies. Karamanska (2008) recently adopted a similar approach and their data 20
confirms the feasibility of a label-free and selective lectin-glycan recognition using SPRi. 21
22
An interesting biotechnological application for screening phage display has been described by 23
Weiss’ and Corn’s groups (Lamboy 2008) using a polyl-lysine-modified surface created 24
by the photopatterning of adsorbed 11-mercaptoundecanoic acid. The peptides Lysn (n=16 to 24) 25
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emerged as optimal for wrapping the phage. The patterned surface was exposed to a solution of 1
phage in water that was allowed to adsorb electrostatically onto the surfaces. Lysn also provided 2
effective wrappers for RNA binding in assays against the RNA-binding protein HIV-1 viral 3
infectivity factor Vif. The oligolysine peptides blocked non-specific binding to allow successful 4
selection and screening of the targets.5
6
6. Concluding remarks7
SPRi represents the forefront of label-free and real-time optical detection of many (up to 8
hundreds) biological interactions simultaneously, furnishing binding profiles for the estimation 9
of the kinetic parameters of the different interactions between immobilised probes and ligands in 10
solution. Most of the immobilisation protocols originate from research on traditional SPR-based 11
biosensing. Applications addressed by SPRi vary from protein-protein interactions, hybridisation12
reactions with DNA, RNA or selected nucleic acids such aptamers with the specific 13
ligands or carbohydrate–lectin interactions. In order to improve sensitivity, signal amplification 14
can be achieved by nanopatterning the sensing surface or by addition of enzyme or nanoparticle-15
labelled reagents, facilitating detection limits down to 1 fM of DNA for point mutation analysis. 16
Given the wide applicability of this emerging technology, some commercial instrumentation has 17
appeared on the market with dedicated ready-to-use chips. Interest in SPRi technology is rising18
quickly and we can expect that it will become important in areas ranging from environmental 19
and food analysis to clinical diagnostics.20
21
Acknowledgments22
Maria Minunni, Coordinator of the project: ”Affinity-Based Biosensing (ABB) for gene doping 23
detection: an integrated approach” would like to thanks World Anti-Doping Agency (WADA) 24
for financial support.25
26
Page 29 of 35
Ac
ce
pte
d M
an
us
cri
pt
22
Bibliography1
Bassil, N., Maillart, E., Canva, M., Lévy, Y., Millot, M.-C., Pissard, S., Narwa, R. & Goossens, 2
M. (2003). Sensors and Actuators B: Chemical, 131, 633-638.3
4
Baute, J. & Depicker, A. (2008). Critical Reviews in Biochemistry and Molecular Biology, 43, 5
239-276.6
7
Berger, C.E.H., Beumer, T.A.M., Kooyman, R.P.H. & Greve, J. (1998). Analytical Chemistry, 8
70, 7703 -7706.9
10
Beusink, J.B., Lokate, A.M., Besselink, G.A., Pruijn, G.J. & Schasfoort, R.B. (2008). 11
Biosensensors and Bioelectronics, 23, 839-844.12
13
Bidan, G., Billon, M., Galasso, K., Livache, T., Mathis, G., Roget, A., Torres-Rodriguez, L.M. 14
& Vieil, E. (2000). Applied Biochemistry and Biotechnology, 89, 183-193.15
16
Bouffartigues, E., Leh, H., Anger-Leroy, M., Rimsky, S. & Buckle, M. (2007). Nucleic Acids 17
Research, 35, e39.18
19
Corne, C., Fiche, J.B., Gasparutto, D., Cunin, V., Suraniti, E., Buhot, A., Fuchs, J., Calemczuk, 20
R., Livache, T. & Favier, A. (2008). Analyst, 133, 1036-1045.21
22
Corne, C., Fiche, J.B., Cunin, V., Buhot, A., Fuchs, J., Calemczuk, R., Favier, A., Livache, T. & 23
Gasparutto, D. (2008a). Nucleic Acids Symposium Series, 249-250.24
25
Cosnier, S. (2003). Analitycal and Bioanalytical Chemistry, 377, 507-520.26
27
D'Agata, R., Corradini, R., Grasso, G., Marchelli, R. & Spoto, G. (2008). Chembiochem, 9, 28
2067-2070.29
30
Di Felice, R. & Selloni, A. (2004). Journal of Chemical Physics, 120, 4906-4914.31
32
Duschl, C., Liley, M., Lang, H., Ghandi, A., Zakeeruddin, S.M., Stahlberg, H., Dubochet, J., 33
Nemetz, A., Knoll, W. & Vogel, H. (1996). Materials Science & Engineering C-Biomimetic 34
Materials Sensors and Systems, 4, 7-18.35
36
Evans, S.D. & Flynn, T.M. (1995). Langmuir, 11, 3811.37
38
Fang, S., Lee, H.J., Wark, A.W. & Corn, R.M. (2006). Journal of American Chemical Society, 39
128, 14044-14046.40
41
Fiche, J.B., Fuchs, J., Buhot, A., Calemczuk, R. & Livache, T. (2008). Analytical Chemistry, 80, 42
1049-1057.43
44
Garcia, B.H.N. & Goodman, R.M. (2008). Journal of Virological Methods, 147, 18-25.45
46
Goodrich, T.T., Lee, H.J. & Corn, R.M. (2004). Journal of American Chemical Society, 126, 47
4086-4087.48
49
Page 30 of 35
Ac
ce
pte
d M
an
us
cri
pt
23
Goodrich, T.T., Lee, H.J. & Corn, R.M. (2004a). Analytical Chemistry, 76, 6173-6178.1
2
Grant, C.F., Kanda, V., Yu, H., Bundle, D.R. & McDermott, M.T. (2008). Langmuir,3
4
Hayashi, G., Hagihara, M. & Nakatani, K. (2008). Journal of Biotechnology, 135, 157-160.5
6
Hickel, W., Kamp, D. & Knoll, W. (1989). Nature, 339, 186.7
8
Homola, J. (2006) Springer-Verlag Berlin and Heidelberg GmbH & Co. K.9
10
Homola, J. (2008). Chemical Reviews, 108, 462-493.11
12
Hottin, J., Moreau, J., Roger, G., Spadavecchia, J., Millot, M.C., Goossens, M. & Canva, M. 13
(2007). Plasmonics, 2, 201-215.14
15
Inamori, K., Kyo, M., Nishiya, Y., Inoue, Y., Sonoda, T., Kinoshita, E., Koike, T. & Katayama, 16
Y. (2005). Analytical Chemistry, 77, 3979-3985.17
18
Jason-Moller, L., Murphy, M. & Bruno, J. (2006). Current Protocols in Protein Science, Chapter 19
19, Unit 19.13.20
21
Jeong, E.J., Jeong, Y.S., Park, K., Yi, S.Y., Ahn, J., Chung, S.J., Kim, M. & Chung, B.H. (2008). 22
Journal of Biotechnology, 135, 16-21.23
24
Jung, S.O., Ro, H.S., Kho, B.H., Shin, Y.B., Kim, M.G. & Chung, B.H. (2005). Proteomics, 5, 25
4427-4431.26
27
Jung, Y., Kang, H.J., Lee, J.M., Jung, S.O., Yun, W.S., Chung, S.J. & Chung, B.H. (2008). 28
Analytical Biochemistry, 374, 99-105.29
30
Jung, Y., Lee, J.M., Jung, H. & Chung, B.H. (2007). Analytical Chemistry, 79, 6534-6541.31
32
Kallwass, H.K.W., Parris, W., McFarlane, E.L.A., Gold, M. & Jones, J.B. (1993). Biotechnology 33
Letters, 15, 29-34.34
35
Kanda, V. & McDermott, M.T. (2004). Analytical Chemistry, 76, 7257-7262.36
37
Karamanska, R., Clarke, J., Blixt, O., Macrae, J.I., Zhang, J.Q., Crocker, P.R., Laurent, N., 38
Wright, A., Flitsch, S.L., Russell, D.A. & Field, R.A. (2008). Glycoconjugate Journal, 25, 69-74.39
40
Kretschmann, E. & Raether, H. (1968). Verlag der Zeitschrift für Naturforschung, 23, 2135-41
2136.42
43
Ladd, J., Taylor, A.D., Piliarik, M., Homola, J. & Jiang, S. (2008a). Analytical Chemistry, 80, 44
4231-4236.45
46
Ladd, J., Taylor, A.D., Piliarik, M., Homola, J. & Jiang, S. (2008). Analytical and Bioanalytical 47
Chemistry, 393, 1157-1163.48
49
Lamboy, J.A., Tam, P.Y., Lee, L.S., Jackson, P.J., Avrantinis, S.K., Jin Lee, H., Corn, R.M. & 50
Page 31 of 35
Ac
ce
pte
d M
an
us
cri
pt
24
Weiss, G.A. (2008). Chem Bio Chem, 9, 2846-2852.1
2
Lecaruyer, P., Mannelli, I., Courtois, V., Goossens, M. & Canva, M. (2006). Analytica Chimica 3
Acta, 573-574, 333-430.4
5
Lee, H.J., Wark, A.W., Li, Y. & Corn, R.M. (2005). Analytical Chemistry, 77, 7832-7837.6
7
Lee, J.M., Park, H.K., Jung, Y., Kim, J.K., Jung, S.O. & Chung, B.H. (2007). Analytical 8
Chemistry, 79, 2680-2687.9
10
Li, Y., Lee, H.J. & Corn, R.M. (2006). Nucleic Acids Research, 34, 6416-6424.11
12
Li, Y., Lee, H.J. & Corn, R.M. (2007). Analytical Chemistry, 79, 1082-1088.13
14
Li, Y., Wark, A.W., Lee, H.J. & Corn, R.M. (2006a). Analytical Chemistry, 78, 3158-3164.15
16
Liu, W., Chen, Y. & Yan, M. (2008). Analyst, 133, 1268-1273.17
18
Lockett, M.R., Weibel, S.C., Phillips, M.F., Shortreed, M.R., Sun, B., Corn, R.M., Hamers, R.J., 19
Cerrina, F. & Smith, L.M. (2008). Journal of American Chemical Society, 130, 8611-8613.20
21
Lokate, A.M., Beusink, J.B., Besselink, G.A., Pruijn, G.J. & Schasfoort, R.B. (2007). Journal of 22
American Chemical Society, 129, 14013-14018.23
24
Löfås, S. & Johnsonn, B. (1990). Journal of the Chemical Society, Chemical Communications 25
article, 1526-1528.26
27
Löfås, S., Johnsonn, B., Edstrom, A., Hansson, A., Lindquist, G. & Müller Hillgren, R.M.S., L. 28
(1995). Biosensors & Bioelectronics, 10, 813-922.29
30
Manera, M.G., Spadavecchia, J., Leone, A., Quaranta, F., Rella, R., Dell’atti, D., Minunni, M., 31
Mascini, M. & Siciliano, P. (2008). Sensors and Actuators B: Chemical, 238, 1129-1145.32
33
Manera, M.G., Rella, R., Spadavecchia, J., Moreau, J. & Canva, M. (2008a). Journal of Optics 34
A: Pure and Applied Optics, 10, 1-6.35
36
Mannelli, I., Lecerf, L., Guerrouache, M., Goossens, M., Millot, M.C. & Canva, M. (2007). 37
Biosensors and Bioelectronics, 22, 803-809.38
39
Mercey, E., Sadir, R., Maillart, E., Roget, A., Baleux, F., Lortat-Jacob, H. & Livache, T. (2008). 40
Analytical Chemistry, 80, 3476-3482.41
42
Minunni, M., Tombelli, S., Fonti, J., Spiriti, M.M., Mascini, M., Bogani, P. & Buiatti, M. (2005). 43
Journal of American Chemical Society, 127, 7966-7967.44
45
Minunni, M., Tombelli, S. & Mascini, M. (2007). Analytical Letters, 40, 1360-1367.46
47
Mori, T., Inamori, K., Inoue, Y., Han, X., Yamanouchi, G., Niidome, T. & Katayama, Y. (2008). 48
Analytical Biochemistry, 375, 223-231.49
50
Page 32 of 35
Ac
ce
pte
d M
an
us
cri
pt
25
Nelson, B.P., Frutos, A.G., Brockman, J.M. & Corn, R.M. (1999). Analytical Chemistry, 71, 1
3928.2
3
Nelson, B.P., Grimsrud, T.E., Liles, M.R., Goodman, R.M. & Corn, R.M. (2001). Analytical 4
Chemistry, 73, 1-7.5
6
Nelson, B.P., Liles, M.R., Frederick, K.B., Corn, R.M. & Goodman, R.M. (2002). 7
Environmental Microbiology, 4, 735-743.8
9
Nishimura, Y., Adachi, H., Kyo, M., Murakami, S., Hattori, S. & Ajito, K. (2005). Bioorganic & 10
Medicinal Chemistry Letters, 15, 2159-2162.11
12
Park, K., Ahn, J., Yi, S.Y., Kim, M. & Chung, B.H. (2008). Biochem Biophys Res Commun, 13
368, 684-689.14
15
Pattnaik, P. (2005). Applied Biochemistry and Biotechnology, 126, 79-92.16
17
Persson, M., Bülow, L. & Mosbach, K. (1990). FEBS Letters, 270, 41-44.18
19
Piliarik, M., Parova, L. & Homola, J. (2008). Biosensors and Bioelectronics,20
21
Quail, J.C., Rako, J.G. & Simon, H.J. (1983). Optics Letters, 8, 377-379.22
23
Rebe Raz, S., Bremer, M.G., Giesbers, M. & Norde, W. (2008). Biosensors and Bioelectronics, 24
24, 552-557.25
26
Ro, H.S., Jung, S.O., Kho, B.H., Hong, H.P., Lee, J.S., Shin, Y.B., Kim, M.G. & Chung, B.H. 27
(2005). Applied and Environmental Microbiology, 71, 1089-1092.28
29
Ro, H.S., Koh, B.H., Jung, S.O., Park, H.K., Shin, Y.B., Kim, M.G. & Chung, B.H. (2006). 30
Proteomics, 6, 2108-2111.31
32
Ross, H., Armstrong, C.G. & Cohen, P. (2002). Biochemical Journal, 366, 977-891.33
34
Ruemmele, J.A., Golden, M.S., Gao, Y., Cornelius, E.M., Anderson, M.E., Postelnicu, L. & 35
Georgiadis, R.M. (2008). Analytical Chemistry, 80, 4752-4756.36
37
Schasfoort, R.B.M. & Tudos, A.J. (2008) . RSC 38
Publishing,39
40
Schroeder, H., Adler, M., Gerigk, K., Muller-Chorus, B., Gotz, F. & Niemeyer, C.M. (2009). 41
Analytical Chemistry, 81, 1275-1279.42
43
Smith, E.A., Thomas, W.D., Kiessling, L.L. & Corn, R.M. (2003). Journal of American 44
Chemical Society, 125, 6140-6148.45
46
Sola-Penna, M., dos Santos, A.C., Alves, G.G., El-Bacha, T., Faber-Barata, J., Pereira, M.F., 47
Serejo, F.C., Da Poian, A.T. & Sorenson, M. (2002). Journal of Biochemical and Biophysical 48
Methods, 50, 129-140.49
50
Page 33 of 35
Ac
ce
pte
d M
an
us
cri
pt
26
Tombelli, S., Minunni, M. & Mascini, M. (2007). Biomolecular Engineering, 24, 191-200.1
2
Tombelli, S., Minunni, M. & Mascini, M. (2005). Methods, 37, 48-56.3
4
Visser, N.F. & Heck, A.J. (2008). Expert Review of Proteomics, 5, 425-433.5
6
Wakao, M., Saito, A., Ohishi, K., Kishimoto, Y., Nishimura, T., Sobel, M. & Suda, Y. (2008). 7
Bioorganic & Medicinal Chemistry Letters, 18, 2499-2504.8
9
Wang, Z., Wilkop, T., Xu, D., Dong, Y., Ma, G. & Cheng, Q. (2007). Analytical and 10
Bioanalytical Chemistry, 389, 819-825.11
12
Wark, A.W., Lee, H.J. & Corn, R.M. (2008). Angewandte Chemie International Edition, 47, 13
644-652.14
15
Wark, A.W., Lee, H.J. & Corn, R.M. (2005). Analytical Chemistry, 77, 3904-3907.16
17
Wassaf, D., Kuang, G., Kopacz, K., Wu, Q.L., Nguyen, Q., Toews, M., Cosic, J., Jacques, J., 18
Wiltshire, S., Lambert, J., Pazmany, C.C., Hogan, S., Ladner, R.C., Nixon, A.E. & Sexton, D.J. 19
(2006). Analytical Biochemistry, 351, 241-253.20
21
Wegner, G.J., Jin-Lee, H. & Corn, R.M. (2004) Surface Plasmon Resonance Imaging 22
Measurements of DNA, RNA, and Protein interactions to Biomolecular Arrays. In 23
Wiley, pp. 107-129.24
25
Wegner, G.J., Lee, H.J., Marriott, G. & Corn, R.M. (2003). Analytical Chemistry, 75, 4740-26
4746.27
28
Williams, A.E., Perry, M.M., Moschos, S.A., Larner-Svensson, H.M. & Lindsay, M.A. (2008). 29
Biochemical Society Transactions, 36, 1211-1215.30
31
Yeatman, E. & Ash, E.A. (1987). Electronics Letters, 23, 1091-1092.32
33
Yuk, J.S., Kim, H.S., Jung, J.W., Jung, S.H., Lee, S.J., Kim, W.J., Han, J.A., Kim, Y.M. & Ha, 34
K.S. (2006). Biosensors and Bioelectronics, 21, 1521-1528.35
36
Page 34 of 35
Ac
ce
pte
d M
an
us
cri
pt
27
Legend to Figures1
2
Fig. 1:3
a) Kretschmann configuration for SPRi; a high refractive index prism is in contact with the 4
detection cell and couples the incident light to the surface plasmons by evanescent waves. p-5
polarised light is directed to the prism, on which the biomolecular probe is tethered, and a CCD 6
camera collects the output signal as variations in reflectivity.7
b) Data are recorded as intensity variation of the reflected light at a fixed angle for each ROI 8
selected. A differential image (left) is produced in real time together with the relative 9
sensorgrams. As example here are reported two sets of signals  corresponding to the interaction 10
with different chemically modified areas. During the specific interaction with the target analyte, 11
only the relative specific probe will react, leading to a local change in intensity of reflected light. 12
This translates into black/white contrast for the image. The unspecific receptor series (used as 13
negative control) will give negligible or none signal.14
c) Sensorgrams corresponding to the interactions of the analyte with the spots on the surface.15
16
Fig. 217
Immobilisation methods using chemical linkers. A self-assembled monolayer is created as the 18
foundation of the array comprising alkaneth L R O V   F R Q W D L Q L Q J  &-terminated amine, hydroxylic or 19
carboxylic functional groups. After the formation of the thiolated layer many immobilisation 20
chemistries can be performed.21
22
Fig. 323
Immobilisation methods exploiting direct attachment of the probe to the gold surface of the chip 24
using thiol- and pyrrole-functionalised biomolecules.25
26
Fig. 427
Signal improvement in SPRi based on mass/colorimetric approaches. The upper diagram shows 28
the DNA hybridisation step followed by addition of streptavidin and biotinylated DNA for signal 29
amplification. In the lower drawing, an aptamer array is exposed to the ligand protein (VEGF) 30
Page 35 of 35
Ac
ce
pte
d M
an
us
cri
pt
28
and then biotinylated antibody forms a sandwich-type assay. The SPRi signal was amplified 1
using an anti-biotin conjugated horseradish peroxidase (HRP) that in presence of a suitable 2
substrate creates a localised dark-blue precipitation reaction.3
4
Fig. 55
Gold nanoparticles for SPRi signal enhancement. The upper drawing shows gold nanoparticles 6
coated with oligonucleotide sequences able to bind the free moiety of the target DNA after the 7
probe/target duplex formation. A similar approach is shown in bottom drawing, in which gold 8
nanoparticles are coated with a poly-T tail able to bind the target sequence on a suitable poly-A 9
end.10
11
Fig. 612
Signal amplification by a “switch on/off” detection strategy: the SPRi signal is produced only if 13
the target sequence fully matches to the specific probe sequence. The array consists of two probe 14
types, differing in the presence or absence of a sequence specific to the SNP. The array is 15
exposed to target solution (blue bars) that contains the ligation probe DNA (orange bar) and Taq 16
DNA ligase (grey round shape). Duplexes that are formed comprise the combination of probe17
(grey bars), target sequence (blue bar) and ligation probe DNA (orange bar) regardless of the 18
presence of the mutation (Step 1). Since ligation occurs only on fully matched duplexes (no 19
SNP), the addition of nanoparticles carrying nucleotide sequence complementary to the ligation 20
probe (Step 2) produces a SPRi signal only if target DNA does not contain the SNP.21
22
Fig. 723
Diagram of the approach proposed by Goodrich and colleagues for the enhancement of SPRi 24
sensitivity. Step 1: a RNA microarray is exposed to target solution containing the enzyme RNase 25
H and the target DNA sequence; Steps 2 and 3: once the RNA/DNA heteroduplexes are formed, 26
RNase H starts to selectively destroy RNA strands in heteroduplexes; Step 4: target DNA strands 27
are released back to into solution and hybridise other free RNA probes on the surface, promoting 28
the their subsequent destruction. The decrease in percent reflectivity becomes larger with time 29
until all of the available RNA probes on the surface are destroyed (Step 6). 30
